Vaxcyte, Inc.
No SEC Form 4 filings for $PCVX in the last 30 days.
New Zealand shares were flat, down 0.1%, as investors awaited company results from Fisher & Paykel Healthcare, Infratil, Ryman Healthcare, Mainfreight and Goodman NZ, plus Fonterra’s opening milk-payout forecast. The Reserve Bank meets Wednesday and the Budget follows next day. Pacific Edge reported revenue down 45% to $13.6m and a $35.8m loss.
FMR LLC has disclosed an 11.4% stake in Vaxcyte (NASDAQ: PCVX), representing beneficial ownership of 16,451,061.32 shares. This information comes from an Amendment No. 9 to a Schedule 13G/A filing, which details voting and dispositive powers held by FMR LLC and Abigail P. Johnson. The filing is administrative and does not indicate a transaction, but rather clarifies ownership structure and authorities.
Vanguard Capital Management has reported a beneficial ownership of 7,252,053 shares of Vaxcyte Inc. common stock, which represents a 5.03% stake in the company. The Schedule 13G filing indicates Vanguard has sole power to dispose of all 7.25 million shares and sole voting power over 985,352 shares. This disclosure, signed on April 30, 2026, reflects a passive investment by the large manager and does not imply any operational changes at Vaxcyte or immediate trading intent.
